The Nijmegen ultra-sensitive Bethesda Assay detects very low-titer factor VIII inhibitors in patients with congenital and acquired hemophilia A
Authors:
- 11 October 2023
- journal article
- research article
- Published by Elsevier in Thrombosis Research
- Vol. 231, 112-120
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Definitions in hemophilia: communication from the SSC of the ISTHJournal of Thrombosis and Haemostasis, 2014
- Hemophilia A in the third millenniumBlood Reviews, 2013
- Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patientsBlood, 2013
- Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition)British Journal of Haematology, 2012
- Low‐titre inhibitors, undetectable by the Nijmegen assay, reduce factor VIII half‐life after immune tolerance inductionJournal of Thrombosis and Haemostasis, 2012
- Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weightBlood, 2012
- Pharmacokinetics of recombinant factor VIII (Kogenate‐FS®) in children and causes of inter‐patient pharmacokinetic variabilityHaemophilia, 2006
- Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study GroupBlood, 2003
- High incidence of anti‐FVIII antibodies against non‐coagulant epitopes in haemophilia A patients: a possible role for the half‐life of transfused FVIIIBritish Journal of Haematology, 1996
- Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIIIThe Lancet, 1993